Table 4.
Patient Characteristics of Previously Reported Cases
Median age at diagnosis (y) | 40 (4–80) |
Gender | |
Male | 74% |
Female | 26% |
Site of glioblastoma | |
Temporal | 28% |
Parietal | 23% |
Occipital | 15% |
Frontal | 23% |
Brainstem | 3% |
Subcortical | 3% |
Cerebellum | 2% |
Hemisphere | 2% |
Basal ganglia | 1% |
Thalamic | 0.5% |
Surgery preceding metastatic diagnosis | |
Yes | 93% |
No | 7% |
Radiation | |
Yes | 88% |
No | 12% |
Chemotherapy | |
Yes | 20% |
No | 80% |
CSF shunt | |
Yes | 11% |
No | 89% |
Site of extracranial metastasis | |
Bone | 12.4% |
Lymph node | 11.5% |
Lung | 10.3% |
Leptomeninges | 5.7% |
Soft tissue | 3.8% |
Liver | 4.1% |
Dural sinus | 3.8% |
Surgical site | 2.3% |
Skin | 2.3% |
Spinal cord | 1.8% |
Systemic vasculature | 1.8% |
Neck | 1.2% |
Parotid gland | 0.9% |
Diaphragm | 0.6% |
Peritoneum | 0.6% |
Spleen | 0.3% |
Kidney | 0.6% |
Pancreas | 0.6% |
Pericardium | 0.6% |
Abdominal wall | 0.3% |
Adrenal gland | 0.3% |
Arm | 0.3% |
Bowel | 0.3% |
Breast | 0.3% |
Chest wall | 0.3% |
Heart | 0.3% |
Mediastinum | 0.3% |
Mesentery | 0.3% |
Pleura | 0.3% |
Pleural fluid | 0.3% |
Orbit | 0.3% |
Nasal cavities | 0.3% |
Muscle | 0.3% |
Median time from symptom onset to diagnosis | 2 (0-60) |
Median time from diagnosis to metastasis | 8 (0-84) |
Median time from metastasis to death | 2.5 (0-30) |
Median OS | 11 (1–92) |